A 3-alkylpyridine-bearing alkaloid exhibits potent antimicrobial activity against methicillin-resistant...

Area of Science:

• Microbiology
• Medicinal Chemistry
• Drug Discovery

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) presents a significant global health threat due to its resistance to existing antibiotics.
• Development of novel antibacterial agents is critical for combating MRSA infections.

Purpose of the Study:

• To evaluate the antibacterial efficacy of five 3-alkyl-pyridinic analogs against MRSA.
• To characterize the mechanism of action, resistance potential, and stability of the most promising compound.

Main Methods:

• Minimum Inhibitory Concentration (MIC) determination for five pyridinic analogs against MRSA.
• Time-kill assays to assess bactericidal kinetics.
• Membrane damage assays, in vitro resistance induction studies, and checkerboard assays for combination therapy.
• Stability testing under various conditions (pH, NaCl, trypsin) and protein binding assessment.
• Biofilm inhibition and biomass reduction assays.
• In vitro selectivity assessment against eukaryotic cells.

Main Results:

• Compound 6 exhibited potent activity against MRSA with MICs ranging from 0.98 to 3.9 μg/mL and rapid bactericidal effects.
• Compound 6 demonstrated membrane-damaging activity, low in vitro resistance potential, and additive effects with vancomycin, ofloxacin, and ciprofloxacin.
• The compound showed stability across various pH, NaCl, and trypsin concentrations, but significant albumin binding; it also inhibited MRSA biofilm formation.

Conclusions:

• Compound 6 is a promising candidate for novel anti-MRSA therapies due to its potent bactericidal activity, membrane-targeting mechanism, and biofilm inhibition.
• Its synergistic potential with existing antibiotics and favorable stability profile warrant further investigation for clinical development.